Advertisement


Tomasz Jankowski, MD, PhD, on Non–Small Cell Lung Cancer: New Data on a Telomere-Targeting Agent

2024 ASCO Annual Meeting

Advertisement

Tomasz Jankowski, MD, PhD, of Poland’s Medical University in Lublin, discusses a phase II study of THIO, a telomere-targeting agent followed by cemiplimab-rwlc for a difficult-to-treat population of patients with advanced non–small cell lung cancer (Abstract 8601).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
TIO represents a groundbreaking first-in-class, small molecule where directed targets telomeres in cancer cells. Specifically those telomeres positive with over 80% of all cancers, and approximately 78-83% of all non-small cell and cancer types being third positive. This innovative approach is particularly significant. TIO operates for a dual mechanism of action. Firstly, it targets telomeres by incorporating itself into newly synthesized telomeres, leading to chromatin uncapping, the generation of DNA damage signals and rapid apoptosis of cancer cells. Secondly, it has an immunogenic effect that enhances the body's immune response against the tumor. In preclinical models sequential treatment with TIO and immune checkpoint inhibitors has demonstrated potent and durable anti-tumor activity, for instance, in non-small cell lung cancer, combining TIO with atezolizumab resulted in a 60% complete response rate with an anti-cancer [inaudible 00:01:08]. In colorectal cancer achieved 100% complete responses with similar promising results in small cell and cancer as well as in hepatocellolar carcinoma. Turning our attention to the TIO-101 trial, it's a phase two dose optimization study for adult patients with advanced or metastatic non-small cell lung cancer who progress or relapse after one to four prior treatments, including immuno and platinum chemotherapy. Using assignment to stage design, 79 patients were assigned to receive one of three doses of TIO. 360, 180 or 60 milligrams, followed by semi-primab every three weeks for up to a year. The combination of TIO and semi-primab has been well tolerated by this heavily pre-treated patients. We have observed significant activity in this difficult to treat group, including both resistant to checkpoint inhibitors and chemotherapy. Importantly, the presence of TIO in circulating tumor cells has shown on target effects. In November, 2023, the ongoing phase two study identified with 180 milligram dose of TIO is the optimal dose, demonstrating better safety and superior efficacy compared to other doses. Specifically, only 9.8% of patients receiving 180 milligram dose reported grade three adverse events related to treatment with no grade four or five adverse events. Per safety profile suggests that TIO could potentially offer a far better alternative to chemotherapy. In terms of efficacy in the third line setting, disease control rate reached 85% for TIO with semi-primab comparing to 25-35% typically observed with standard chemotherapy. We have also seen long-term responses. With five patients having survival follow up for over 12 months, three of them are still on treatment. The median survey will follow up in the third line is 9.1 months. Moreover, overall response rate in the third line with dose 180 milligrams of TIO was 38%, comparing to about 6% for other treatment possibilities. In conclusion, the safety and efficacy achievements of TIO are truly promising. We are confirming many of the assumptions [inaudible 00:03:18] observed in the pre-clinical studies, and we are looking forward to follow up our patients.

Related Videos

Breast Cancer

Emily L. Podany, MD, on Metastatic Breast Cancer: Racial Differences in Genomic Profiles and Targeted Treatment Use

Emily L. Podany, MD, of Washington University, St. Louis, discusses disparities in the use of PI3K inhibitors for Black patients with estrogen receptor–positive, HER2-negative metastatic breast cancer while other drugs that do not require genomic profiling were similarly used (Abstract 1017). 

Multiple Myeloma

Suzanne Trudel, MD, on Multiple Myeloma: Results From the DREAMM-8 Study of Treatments After Relapse

Suzanne Trudel, MD, of Canada’s Princess Margaret Cancer Centre, discusses phase III findings showing that, in patients with relapsed or refractory multiple myeloma who had one or more prior lines of treatment, belantamab mafodotin-blmf plus pomalidomide and dexamethasone improved progression-free survival and showed a favorable overall survival trend compared with pomalidomide plus bortezomib and dexamethasone.

Skin Cancer

Omid Hamid, MD, on Cutaneous Melanoma: Update on a Bispecific Protein Under Study

Omid Hamid, MD, of The Angeles Clinic and Research Institute, a Cedars-Sinai affiliate, discusses updated data on IMC-F106C, a novel bispecific protein that, in a phase I safety and efficacy study, exhibited clinical activity in patients with unresectable or metastatic cutaneous melanoma who were pretreated with immune checkpoint inhibitors. A phase III trial of IMC-F106C with nivolumab in the first-line setting of metastatic disease has been initiated (NCT06112314; Abstract 9507).

Leukemia
Lymphoma

William G. Wierda, MD, PhD, on CLL/SLL: Updated Findings on Ibrutinib and Venetoclax

William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses up to 5.5 years of follow-up data from the phase II CAPTIVATE study, showing that in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), fixed duration ibrutinib plus venetoclax continues to provide clinically meaningful progression-free disease in those with high-risk genomic features as well as in the overall population (Abstract 7009).

Prostate Cancer

Christos Kyriakopoulos, MD, on Prostate Cancer: CHAARTED2 Trial Results on Cabazitaxel and Abiraterone

Christos Kyriakopoulos, MD, of the University of Wisconsin Carbone Cancer Center, discusses data suggesting that adding cabazitaxel to abiraterone and prednisone improves progression-free survival in patients with metastatic castration-resistant prostate cancer who previously received chemohormonal therapy with docetaxel for hormone-sensitive disease compared with abiraterone plus prednisone alone (Abstract LBA5000).

Advertisement

Advertisement




Advertisement